Trump Administration Ends Pharmacy Coupons When Patients Need Them Most


By Peter J. Pitts

For chronically ill Americans, the economic damage from COVID-19 could be nearly as life-threatening as the virus itself. More than 40 million workers have filed for unemployment since the beginning of the outbreak. For many, the financial challenges of joblessness have made it harder than ever to afford their insurance companies' medication copays.

That's why a new decision from the Trump administration couldn't have come at a worse time. The rule, which was finalized in May, enables insurers to artificially inflate patients' out-of-pocket drug costs. In so doing, it creates unnecessary challenges for Americans who are already struggling to stay healthy.

For many patients, high pharmacy bills were a heavy burden even before COVID-19. A November Kaiser Family Foundation survey found that half of patients in poor health had difficulty paying for their medications. Three in ten reported skipping doses for financial reasons.

This "non-adherence" causes 125,000 deaths each year and as many as a quarter of hospitalizations. It also inflates U.S. healthcare spending by up to $289 billion annually.

Now that coronavirus lockdowns have sent our economy into a tailspin, drug adherence rates are likely to plummet further as Americans look for new ways to make ends meet.

Consider that a quarter of the country has dipped into savings in recent weeks, while 14 percent have borrowed money from friends or family, per Northwestern Mutual. It's only a matter of time before large numbers of Americans stop filling the prescription medicines they need.

In times like these, helping the hardest-hit patients take their medications ought to be a top priority. Yet the Trump administration has done precisely the opposite. The new rule from the Centers for Medicare and Medicaid Services (CMS) would help insurance companies nullify the prescription drug coupons that make medicines affordable for millions of Americans.

In many health plans, patients pay for their own drugs up to a certain limit, known as a deductible, after which they are responsible for a smaller copay. The patient remains on the hook for those copays until he or she reaches the federally mandated out-of-pocket limit, which in 2020 was $16,300 for families.

To help defray out-of-pocket costs, drug firms usually offer generous coupons on brand-name medications.

For cash-strapped patients, these discounts can be life-changing. About a fifth of commercially insured patients use coupons to lower their pharmacy costs. These coupons cut out-of-pocket drug spending by $13 billion in 2018. Just as important, drug coupons have been shown to increase adherence for everything from cholesterol medication to anti-inflammatory drugs.

These coupons only benefit patients if they count towards the out-of-pocket limit. Otherwise, patients would still be on the hook for huge pharmacy bills.

Unfortunately, the new CMS rule allows insurers to stop counting coupons towards the out-of-pocket cap. That means insurance giants will extract more money out of struggling Americans' pockets.

Officials in states like Virginia, West Virginia, Illinois, and Arizona have already banned this practice. Unless other states follow suit -- or Congress intervenes and passes legislation nullifying the rule -- millions of Americans could face higher pharmacy bills while battling the worst financial crisis since the Great Depression.

Barring intervention, America could face a pandemic of non-adherence that puts millions of lives at risk. Unlike COVID-19, this new public health emergency won't be caused by a wily virus, but by the callousness of Washington policymakers.

Peter J. Pitts, a former FDA associate commissioner, is president of the Center for Medicine in the Public Interest.

More Resources


03/28/2024
The Democrats' Abundance Problem Revisited
So, Um, Where Is It?

more info


03/28/2024
Are Democrats Still Stuck With Biden?


more info


03/28/2024
RFK Jr. Now Hurting Biden, Helping Trump


more info


03/28/2024
The Twilight of the Republican 'McLeadership'
The Trump team is steadily purging the Republican leadership of holdovers from past decades. The departure of McCarthy, McDaniel, and McConnell is part of exorcising the legacy of a more important Mc whose influence is still felt in the U.S. Senate: John McCain.

more info


03/28/2024
The Funniest Media Story of the Year?
Surely this is the funniest media story of the year?

more info


03/28/2024
Abridging, Not Coercing, Is First Amendment's Yardstick
Under the First Amendment, the government may not abridge the freedom of speech, whether that abridging is done by coercing internet platforms or by getting them to cooperate in government efforts to censor the public.

more info


03/28/2024
Trade Cheaters Are Killing Aluminum Industry Jobs
Aluminum industry workers stand ready to do their part to move the nation forward. They just need the federal government to enforce trade laws.

more info


03/28/2024
It's Time for an Immigration Moratorium
An effective freeze on immigration could revitalize our national culture, politics, and economy before it's too late.

more info


03/28/2024
U.N. Gaza Resolution Could Lead to Lasting Cease-Fire


more info


03/28/2024
Biden's War Against the Jews


more info


03/28/2024
'Fairness Initiative' Tackles Too-High Government Pay
Governments at every level ought to cap public-sector wages and benefits at private-sector comparables.

more info


03/28/2024
My Friend Joe
I write now, in the worst pain and shock, with news of my friend Joe Lieberman's death just moments ago. I write because I know what his critics will be quick to write, what news reports have already re-circulated.

more info


03/28/2024
Why I'm Resigning From the Biden State Department
Since Hamas' attack on October 7, Israel has used American bombs in its war in Gaza, which has killed more than 32,000 people - 13,000 of them children - with countless others buried under the rubble, according to the Gaza Ministry of Health. Israel is credibly accused of starving the 2 million people who remain, according to the UN special rapporteur on the right to food; a group of charity leaders warns that without adequate aid, hundreds of thousands more will soon likely join the dead.

more info


03/28/2024
Gaza: Truths Behind All the Lies
From civilian casualties, the use of disproportionate force, and international biases, the mainstream narrative of the Gaza conflict often obfuscates the truth behind lies.

more info


03/28/2024
Obama, Fearing Biden Loss to Trump, Is On Phone To Strategize
As the election approaches, President Joe Biden is making regular calls to former President Barack Obama to catch up on the race or to talk about family. But Obama is making calls of his own to Jeffrey Zients, the White House chief of staff, and to top aides at the Biden campaign to strategize and relay advice.

more info



Custom Search

More Politics Articles:

Related Articles

Congress: Let's Talk About Trade Enforcement


The Trump administration has set an ambitious trade agenda for the remainder of 2020. In a House Ways and Means Committee hearing earlier this summer, U.S. Trade Representative Robert Lighthizer stressed the president's intent to crack down on foreign countries that discriminate against American business and innovators.

With Biomedical Research, Taxpayers are Getting a Great Deal


Gilead Sciences' novel drug remdesivir has shown immense promise for treating coronavirus. Yet every time a company develops a promising drug, some policymakers call for the government to take control of the compound in question.

Marx on Christianity, Judaism, and Evolution/Race


"If someone calls it socialism," said the Rev. William Barber at an August 2019 conference of the Democratic National Committee, "then we must compel them to acknowledge that the Bible must then promote socialism, because Jesus offered free health care to everyone, and he never charged a leper a co-pay."

Abusing March-in Rights Would Jeopardize COVID-19 Research


Thirty-one state attorneys general recently urged the Trump administration to disregard the intellectual property protections on remdesivir -- the only FDA-approved treatment for COVID-19 -- and then license its patents to multiple drug manufacturers.

Judge Amy Coney Barrett and the Purdue Sexual Assault Case


Will some senators on the Senate Judiciary Committee vilify Judge Amy Coney Barrett, President Trump's Supreme Court nominee? Attacks on her religion, her large family, or claims that she will block the advance of women may make good fodder for Facebook, but senators who pursue those tacks are likely to reap public disapproval from their own constituents. What is more likely is that liberal senators will take a page from liberal/progressive organizations like Public Justice and portray Barrett as soft on and complicit with campus sexual abusers. How?

President Trump's Executive Order Will Put an End to Pharmaceutical Breakthroughs


Every day, scientists get closer to a COVID-19 vaccine. A handful of biopharmaceutical firms hope to make one available by year's end.

The Mayflower Mystique: Remembering the Pilgrims


Few can name which groups the Godspeed and the Arabella brought to America. They were the Jamestown colonists in 1607 and the Puritans to Massachusetts Bay Colony in 1630, respectively. But the Mayflower, which brought the Pilgrims to Plymouth in 1620, has sailed into history and ranks with the Titanic, the Lusitania, the Bismarck, and the Queen Mary as the world’s most famous ships. What accounts for the Mayflower’s mystique?

COVID's Second Wave Underscores the Threats Facing Disabled Americans


The second wave of COVID-19 has arrived with a vengeance.

Triumph of the Vaccine—No Shape-Shifting Enemy


Here’s a thought experiment. What if our experience with COVID-19 turns out to be a warm-up for responding to a worse plague in the future? COVID-19 is devastating for a significant number of older people but relatively innocuous for the young. I am thankful that this is not like the Justinian plague, nor the Athenian one, nor like smallpox. What if—God forbid—we find ourselves hosting a plague like one of these? Something as deadly as Ebola but as infectious as SARS-CoV-2?

Who is Perfect? Biden, Trump, McConnell, Pelosi?


Democrats have proven once again that they can find fault in President Donald Trump. Faults and flaws were found in him before the election. Many years before politics there were never any rave reviews about him being perfect.

The 340B Prescription-Drug Swindle Has Gone on Long Enough


In a recent hearing, California Attorney General Xavier Becerra revealed just how unfit he is to lead the Department of Health and Human Services.

Vaccination is the Ticket to Getting the U.S. Back On Track


The end of the pandemic in the U.S. is in sight. The Covid-19 vaccines currently available in the United States have proven to be outstandingly effective at protecting recipients from coronavirus and they are also safe.

Private Deborah Sampson, 'The Female Soldier'


There are those who would say that Private Deborah Sampson deserved the Medal of Honor, but she didn’t sign up for that; she joined the Army to fight for her country and wound up making history. Private Sampson was America’s first woman combat soldier. She served, disguised as a man by the name of Robert Shurtleff, under the command of General George Washington in the Continental Army during the American Revolution.

The End of Covid-19 Could Start in the Hair Salon


President Biden has floated an ambitious goal -- vaccinate enough Americans to achieve some sense of normalcy by July 4.

President Biden Is Right to Redefine Infrastructure


President Biden is in ongoing talks to discuss his multi-trillion-dollar infrastructure plan. Ever since its release, critics have claimed that many aspects of the plan have nothing to do with infrastructure.

America Needs Strong Patent Laws to Keep Inventing


In May, the Biden administration announced its support for a proposal at the World Trade Organization to suspend international intellectual property protections on Covid-19 vaccines.